Current pharmacologic therapies and emerging alternatives in the treatment of ulcerative colitis

Tetsuya Nakamura, Masakazu Nagahori, Takanori Kanai, Mamoru Watanabe

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Recent progress in both basic and clinical research has led us to develop sophisticated and effective medical therapy of ulcerative colitis (UC). Although classical agents such as aminosalicylates, corticosteroids and immunomodulatory drugs have remained as the gold standard for decades, their novel formulations and/or dosage regimens have changed their placements in the medical management of UC. In addition, studies have shown that a number of novel therapeutic agents, designed to target specific mechanisms involved in the inflammatory cascade, have efficacy for the treatment of UC and they will have significant clinical impacts in the near future. A clear understanding of the proven and potential benefits of both the standard and emerging therapies will be required for the optimum individual care of patients with varied clinical presentations.

Original languageEnglish
Pages (from-to)36-41
Number of pages6
JournalDigestion
Volume77
Issue numberSUPPL. 1
DOIs
Publication statusPublished - 2008 Jan 1
Externally publishedYes

Keywords

  • Aminosalicylates
  • Biologic therapy
  • Corticosteroids
  • Immunosuppressants
  • Ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Current pharmacologic therapies and emerging alternatives in the treatment of ulcerative colitis'. Together they form a unique fingerprint.

  • Cite this